Skip to main content

Table 3 Parent-reported outcomes at cross-sectional visit in patients still receiving ETN

From: Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

  No assessed  
Median (IQR) physical function scorea 420 0 (0; 3)
No (%) of patients with physical function score = 0 420 220 (52.4)
Median (IQR) HRQL scoreb 417 2 (0; 5)
No (%) of patients with HRQL score > 1 DS above the mean of healthy children 417 92 (22.1)
Median (IQR) HRQL PhH scorec 417 1 (0; 3)
No (%) of patients with HRQL PhH score > 1 DS above the mean of healthy children 417 203 (48.7)
Median (IQR) HRQL PsH scorec 417 1 (0; 3)
No (%) of patients with HRQL PsH > 1 DS above the mean of healthy children 417 82 (19.7)
Median (IQR) VAS well-beingd 420 0.5 (0; 3)
No (%) of patients with VAS well-being = 0 420 193 (46)
Median (IQR) VAS paind 420 0 (0; 2,5)
No (%) of patients with VAS pain = 0 420 215 (51.2)
No (%) of patients with VAS pain ≤1 420 289 (68.8)
No (%) of patients with VAS pain from 1.5 to 5 420 99 (23.6)
No (%) of patients with VAS pain >5 420 32 (7.6)
Median (IQR) VAS disease activityd 420 0 (0; 2)
No (%) of patients with VAS disease activity = 0 420 224 (53.3)
No (%) of patients with no morning stiffness 420 319 (76)
Disease activity state
 No (%) of patients with remission 421 286 (67.9)
 No (%) of patients with continued activity 421 86 (20.4)
 No (%) of patients with disease flare 421 49 (11.6)
No (%) of parents satisfied with their child’s illness outcome 399 330 (82.7)
  1. IQR interquartile range, HRQL health-related quality of life, PhH Physical Health, PsH Psychosocial Health, VAS visual analog scale
  2. aScore ranges from 0 (no disability) to 30 (maximum disability)
  3. bScore ranges from 0 to 30, higher scores indicate worse HRQL
  4. cScore ranges 0–15, higher scores indicate worse HRQL
  5. dAll VAS range from 0 (best) to 10 (worst)